Onpattro

Generic name: Patisiran
Drug class: Miscellaneous metabolic agents

Usage of Onpattro

Onpattro a double-stranded small interfering ribonucleic acid (siRNA), formulated as a lipid complex injection.

Onpattro is a prescription medicine used to treat adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR) (damage of multiple nerves throughout the body).

Onpattro is given by intravenous (IV) infusion.

Onpattro side effects

Get emergency medical help if you have signs of an allergic reaction to Onpattro: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Some side effects may occur during the injection. Tell your medical caregiver if you feel warm, dizzy, nauseated, light-headed, itchy, sweaty, or have a headache, chest tightness, back pain, trouble breathing, or swelling in your face.

Common Onpattro side effects may include:

cold symptoms such as stuffy nose, sneezing, sore throat.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Before taking Onpattro

Before using Onpattro tell your doctor about all your medical conditions or allergies.

Patisiran may harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant.

If you are pregnant, your name may be listed on a pregnancy registry to track the effects of patisiran on the baby.

It may not be safe to breastfeed while using this medicine. Ask your doctor about any risk.

Relate drugs

How to use Onpattro

Usual Adult Dose for Amyloidogenic Transthyretin Amyloidosis:

Dosing is based on actual body weight; premedication should be given at least 60 minutes prior to the start of the infusion Weight less than 100 kg: 0.3 mg/kg via IV infusion every 3 weeks Weight 100 kg or greater: 30 mg via IV infusion every 3 weeks Initial infusion rate should be approximately 1 mL/min for the first 15 minutes, then increase to approximately 3 mL/min for the remainder of the infusion; in the event of an infusion related reaction, the duration of infusion may be extended; see administration advice for infusion instructions PREMEDICATION: Administer on day of infusion at least 60 minutes prior to start of infusion: -Acetaminophen 500 mg orally -IV corticosteroid (e.g., Dexamethasone 10 mg or equivalent) -IV H1 blocker (e.g. diphenhydramine 50 mg or equivalent) -IV H2 blocker (e.g., ranitidine 50 mg or equivalent) Comments: -Premedications are required to reduce the risk of infusion related reactions (IRR). -If IV premedications are not available or not tolerated, oral equivalents may be used -If patients are tolerating the infusion, but experiencing adverse reactions to corticosteroid premedication, reduce corticosteroid in 2.5 mg increments to a minimum IV dose of dexamethasone 5 mg or equivalent -Some patients may require additional or higher doses of one or more premedications to reduce the risk of IRRs. Use: For the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis.

Warnings

Follow all directions on your medicine label and package. Tell each of your healthcare providers about all your medical conditions, allergies, and all medicines you use.

What other drugs will affect Onpattro

Other drugs interact with Onpattro, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using.

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.